{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"16.4","upperLimit":"29.0","value":"3.3"},{"groupId":"OG001","lowerLimit":"21.3","upperLimit":"34.7","value":"7.2"},{"groupId":"OG002","lowerLimit":"1.9","upperLimit":"8.6","value":"0.0"}]}],"title":"Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.9"},{"groupId":"OG001","value":"20.4"},{"groupId":"OG002","value":"4.5"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.7"},{"groupId":"OG001","value":"14.9"},{"groupId":"OG002","value":"19.0"}]}],"title":"Stable Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.7"},{"groupId":"OG001","value":"47.5"},{"groupId":"OG002","value":"61.5"}]}],"title":"Progressive Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.3"},{"groupId":"OG001","value":"9.9"},{"groupId":"OG002","value":"15.1"}]}],"title":"Not Evaluable"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6"},{"groupId":"OG001","value":"0.0"},{"groupId":"OG002","value":"0.0"}]}],"title":"No Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6"},{"groupId":"OG001","value":"0.0"},{"groupId":"OG002","value":"0.0"}]}],"title":"No Assessment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"180"},{"groupId":"OG001","value":"181"},{"groupId":"OG002","value":"179"}],"units":"Participants"}],"description":"BOR was assessed by independent radiology review using RECIST 1.1 and was recorded from randomization until the last imaging assessment in this period. Response categories included: Complete Response (CR): disappearance of all target lesions; Partial Response (PR): at least a 30% decrease in the sum of diameters of target lesions; Progressive Disease (PD): at least a 20% increase in the sum of diameters of target lesions; and Stable Disease (SD): neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. BOR for the Initial Treatment Period was based on IRO. BOR for participants during the Initial Treatment Period is presented.","groups":[{"description":"Participants were initially randomized to receive pembrolizumab 2 mg/kg IV Q3W. With Amendment 03, this dosing was discontinued and all study participants were to be treated with fixed-dose open label pembrolizumab 200 mg IV Q3W. Participants were to receive study drug until discontinuation due to progression of disease, toxicity, or choice. (Up to \\~66 months)","id":"OG000","title":"Pembrolizumab 2 mg/kg"},{"description":"Participants were initially randomized to receive pembrolizumab 10 mg/kg IV Q3W. With Amendment 03, this dosing was discontinued and all study participants were to be treated with fixed-dose open label pembrolizumab 200 mg IV Q3W. Participants were to receive study drug until discontinuation due to progression of disease, toxicity, or choice. (Up to \\~66 months)","id":"OG001","title":"Pembrolizumab 10 mg/kg"},{"description":"Participants were initially randomized to receive 1 of 4 possible chemotherapy regimens decided at the treating institution (carboplatin+paclitaxel, paclitaxel alone, dacarbazine, or temozolomide). Participants were to receive study drug until discontinuation due to progression of disease, toxicity, or choice. (Up to \\~66 months)","id":"OG002","title":"Investigator-Choice Chemotherapy (ICC)"}],"paramType":"NUMBER","populationDescription":"The analysis population consisted of all randomized participants. Participants were included in the initial treatment group to which they were randomized for the efficacy analysis.","reportingStatus":"POSTED","timeFrame":"Up to approximately 36 months (Through Final Analysis database cutoff date of 16-Nov-2015)","title":"Best Overall Response (BOR) - Initial Treatment Period","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}